179 related articles for article (PubMed ID: 27261467)
1. A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors.
Jin N; Lubner SJ; Mulkerin DL; Rajguru S; Carmichael L; Chen H; Holen KD; LoConte NK
Oncologist; 2016 Jul; 21(7):785-6. PubMed ID: 27261467
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY
Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.
Baertsch MA; Hillengass J; Blocka J; Schönland S; Hegenbart U; Goldschmidt H; Raab MS
Hematol Oncol; 2018 Feb; 36(1):210-216. PubMed ID: 28685863
[TBL] [Abstract][Full Text] [Related]
4. E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors.
Lubner S; Feng Y; Mulcahy M; O'Dwyer P; Giang GY; Hinshaw JL; Deming D; Klein L; Teitelbaum U; Payne J; Engstrom P; Stella P; Meropol N; Benson A
Oncologist; 2018 Sep; 23(9):1006-e104. PubMed ID: 29853660
[TBL] [Abstract][Full Text] [Related]
5. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer.
de Marinis F; Atmaca A; Tiseo M; Giuffreda L; Rossi A; Gebbia V; D'Antonio C; Dal Zotto L; Al-Batran SE; Marsoni S; Wolf M
J Thorac Oncol; 2013 Aug; 8(8):1091-4. PubMed ID: 23857399
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Mitry E; Walter T; Baudin E; Kurtz JE; Ruszniewski P; Dominguez-Tinajero S; Bengrine-Lefevre L; Cadiot G; Dromain C; Farace F; Rougier P; Ducreux M
Eur J Cancer; 2014 Dec; 50(18):3107-15. PubMed ID: 25454413
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.
Ibrahim N; Buchbinder EI; Granter SR; Rodig SJ; Giobbie-Hurder A; Becerra C; Tsiaras A; Gjini E; Fisher DE; Hodi FS
Cancer Med; 2016 Nov; 5(11):3041-3050. PubMed ID: 27748045
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
[TBL] [Abstract][Full Text] [Related]
11. The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors.
Cassier PA; Floquet A; Penel N; Derbel O; Bui N'guyen B; Guastalla JP; Pissaloux D; Treilleux I; Saba CE; Blay JY; Ray-Coquard I
Ann Oncol; 2014 May; 25(5):1074-5. PubMed ID: 24651409
[No Abstract] [Full Text] [Related]
12. Panobinostat-A Potential Treatment for Metastasized Ewing Sarcoma? A Case Report.
van Maldegem AM; Bovée JV; Gelderblom H
Pediatr Blood Cancer; 2016 Oct; 63(10):1840-3. PubMed ID: 27245095
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.
Imai Y; Ohta E; Takeda S; Sunamura S; Ishibashi M; Tamura H; Wang YH; Deguchi A; Tanaka J; Maru Y; Motoji T
JCI Insight; 2016 Apr; 1(5):e85061. PubMed ID: 27699258
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.
Rathkopf DE; Picus J; Hussain A; Ellard S; Chi KN; Nydam T; Allen-Freda E; Mishra KK; Porro MG; Scher HI; Wilding G
Cancer Chemother Pharmacol; 2013 Sep; 72(3):537-44. PubMed ID: 23820963
[TBL] [Abstract][Full Text] [Related]
15. In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers.
Maschauer S; Gahr S; Gandesiri M; Tripal P; Schneider-Stock R; Kuwert T; Ocker M; Prante O
Nucl Med Biol; 2016 Jan; 43(1):27-34. PubMed ID: 26702784
[TBL] [Abstract][Full Text] [Related]
16. Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study.
Barnes JA; Redd R; Fisher DC; Hochberg EP; Takvorian T; Neuberg D; Jacobsen E; Abramson JS
Hematol Oncol; 2018 Oct; 36(4):633-637. PubMed ID: 29956350
[TBL] [Abstract][Full Text] [Related]
17. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial.
Tan D; Phipps C; Hwang WY; Tan SY; Yeap CH; Chan YH; Tay K; Lim ST; Lee YS; Kumar SG; Ng SC; Fadilah S; Kim WS; Goh YT;
Lancet Haematol; 2015 Aug; 2(8):e326-33. PubMed ID: 26688485
[TBL] [Abstract][Full Text] [Related]
18. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Cheng T; Grasse L; Shah J; Chandra J
Drugs Today (Barc); 2015 Aug; 51(8):491-504. PubMed ID: 26380387
[TBL] [Abstract][Full Text] [Related]
19. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics and histone deacetylase inhibitors.
Goey AK; Sissung TM; Peer CJ; Figg WD
Pharmacogenomics; 2016 Nov; 17(16):1807-1815. PubMed ID: 27767376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]